Melissa Schoelwer, MD, MSCR
Dr. Melissa Schoelwer is a pediatric endocrinologist with a passion for caring for children with type 1 diabetes. She primarily see patients with diabetes and other endocrine disorders at UVA Children’s Hospital. Dr. Schoelwer is involved in a number of artificial pancrease studies at the Center for Diabetes Technology and is interested in improving glycemic control and quality of life in children of all ages with T1D through the use of diabetes technology. She is an enthusiastic supporter of diabetes camps and have participanted in camps at all stages of my education and training, including here in Charlottesville at our local camp, Camp Holiday Trails.
- MD, Indiana University School of Medicine (2010)
- Pediatrics Residency – Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University (2013)
- Pediatric Endocrinology Fellowship – Riley Hospital for Children, Indiana University (2016)
- Master of Science in Clinical Research – Indiana University (2016)
- Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort (Co-Investigator)
- Artificial Pancreas – Adolescent Physiology and Psychology Longitudinal Evaluation (A.P. APPLE) (Co-investigator)
- The Pediatric Artificial Pancreas (PEDAP) trial: A Randomized Controlled Comparison of the Control-IQ technology Versus Standard of Care in Young Children in Type 1 Diabetes (Co-investigator)
- Clinical Validation of a Smart Bolus Calculator Informed by Insulin Sensitivity in Adults and Adolescents with Type 1 Diabetes (Co-investigator)
- Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas Using Total Daily Insulin (Co-investigator)
- The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas in Pediatrics (Site PI)
- Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics (Co-investigator)
Dr. Melissa Schoelwer teach medical students, residents, and fellows as they rotate through my clinic. Additionally, she frequently give lectures on pediatric diabetes to medical students, both at UVA and at Camp Holiday Trails.
- Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD*; iDCL Trial Research Group. Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technol Ther. 2021.
- Schoelwer MJ, DeBoer MD. Artificial Pancreas Technology Offers Hope for Childhood Diabetes. Curr Nutr Rep. 2021 Jan 7
- Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP*; iDCL Trial Research Group. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020 Aug 27;383(9):836-845.
- Ekhlaspour L, Schoelwer MJ, Forlenza GP, Deboer MD, Norlander L, Hsu L, Kingman R, Boranian E, Berget C, Emory E, Buckingham BA, Breton MD, Wadwa RP*. Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers. Diabetes Technol Ther. 2020 Dec 8.
- Schoelwer MJ, Robic JL, Gautier T, Fabris C, Carr K, Clancy-Oliveri M, Brown SA, Anderson SM, DeBoer MD, Cherñavvsky DR, Breton MD*. Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes. Diabetes Technol Ther. 2020 Aug;22(8):594-601.
Other publications can be found here.